Search Results - "V V Semiglazov"

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study by Gianni, L., Huang, C.S., Egle, D., Bermejo, B., Zamagni, C., Thill, M., Anton, A., Zambelli, S., Bianchini, G., Russo, S., Ciruelos, E.M., Greil, R., Semiglazov, V., Colleoni, M., Kelly, C., Mariani, G., Del Mastro, L., Maffeis, I., Valagussa, P., Viale, G.

“…High-risk triple-negative breast cancers (TNBCs) are characterized by poor prognosis, rapid progression to metastatic stage and onset of resistance to…”
Get full text

General recommendations for the management of breast cancer (St. Gallen Expert Consensus developed at the 16th th International Breast Cancer Conference) by Semiglazov, V. F., Paltuev, R. M., Semiglazov, V. V.

“…This article summarizes the results of the 16th St. Gallen International Breast Cancer Conference (March 2019), which traditionally resulted in the development…”
Get full text

DIAGNOSIS AND TREATMENT OF BREAST CANCER IN SITU. RUSSIAN ASSOCIATION OF ONCOLOGICAL MAMMOLOGY CLINICAL GUIDELINES (PROJECT) by Semiglazov, V. V.

“…One of the first and foremost tasks of the Russian Association of Oncological Mammology (RAOM) is to develop clinical guidelines on diagnosis and treatment of…”
Get full text

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006 by Kaufmann, M., von Minckwitz, G., Bear, H.D., Buzdar, A., McGale, P., Bonnefoi, H., Colleoni, M., Denkert, C., Eiermann, W., Jackesz, R., Makris, A., Miller, W., Pierga, J.-Y., Semiglazov, V., Schneeweiss, A., Souchon, R., Stearns, V., Untch, M., Loibl, S.

“…Neoadjuvant (primary systemic) treatment has become a standard option for primary operable disease for patients who are candidates for adjuvant systemic…”
Get full text

Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy by Blackwell, K., Semiglazov, V., Krasnozhon, D., Davidenko, I., Nelyubina, L., Nakov, R., Stiegler, G., Singh, P., Schwebig, A., Kramer, S., Harbeck, N.

“…Biosimilars of filgrastim are in widespread clinical use in Europe. This phase III study compares biosimilar filgrastim (EP2006), with the US-licensed…”
Get full text

Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study by Jackisch, C., Kim, S.-B., Semiglazov, V., Melichar, B., Pivot, X., Hillenbach, C., Stroyakovskiy, D., Lum, B.L., Elliott, R., Weber, H.A., Ismael, G.

“…HannaH revealed consistent overall safety profiles between fixed-dose subcutaneous (s.c.) and weight-based intravenous (i.v.) trastuzumab (median follow-up 20…”
Get full text

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer by Baselga, J., Manikhas, A., Cortés, J., Llombart, A., Roman, L., Semiglazov, V.F., Byakhov, M., Lokanatha, D., Forenza, S., Goldfarb, R.H., Matera, J., Azarnia, N., Hudis, C.A., Rozencweig, M.

“…Nonpegylated liposomal doxorubicin liposomal doxorubicin, (Myocet™; Sopherion Therapeutics, Inc Canada, and Cephalon, Europe) (NPLD; Myocet®) in combination…”
Get full text

Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial by Bianchini, G., Pusztai, L., Pienkowski, T., Im, Y.-H., Bianchi, G.V., Tseng, L.-M., Liu, M.-C., Lluch, A., Galeota, E., Magazzù, D., de la Haba-Rodríguez, J., Oh, D.-Y., Poirier, B., Pedrini, J.L., Semiglazov, V., Valagussa, P., Gianni, L.

“…To investigate in the NeoSphere trial the contribution of the immune system to pathologic complete response in the breast (pCRB) after neoadjuvant docetaxel…”
Get full text

A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results by Pivot, X., Bondarenko, I., Nowecki, Z., Dvorkin, M., Trishkina, E., Ahn, J.-H., Im, S.-A., Sarosiek, T., Chatterjee, S., Wojtukiewicz, M.Z., Shparyk, Y., Moiseyenko, V., Bello, M., Semiglazov, V., Lee, Y., Lim, J.

“…The equivalent efficacy between SB3, a proposed trastuzumab biosimilar, and the trastuzumab reference product (TRZ) in terms of the breast pathologic complete…”
Get full text

The role of platinum-based antineoplastic drugs and their impact on complete pathological response and prognosis in patients with BRCA-associated triple-negative breast cancer after neoadjuvant treatment: a single institution experience by Enaldieva, D. A., Krivorotko, P. V., Imyanitov, E. N., Zhiltsova, E. K., Donskikh, R. V., Sokolenko, A. P., Shaykhelislamova, L. F., Tabagua, T. T., Gigolaeva, L. P., Komyakhov, A. V., Nikolaev, K. S., Zernov, K. Yu, Ereshchenko, S. S., Paltuev, R. M., Bessonov, A. A., Artemyeva, A. S., Pesotskiy, R. S., Amirov, N. S., Emelyanov, A. S., Mortada, V. V., Bondarchuk, Ya. I., Semiglazov, V. V., Semiglazova, T. Yu, Semiglazov, V. F., Belyaev, A. M.

“…   Background.  BRCA-associated triple negative breast cancer (TNBC) is considered one of the most aggressive subtypes of breast cancer with high sensitivity…”
Get full text

Strategy of post-neoadjuvant treatment of patients with residual breast cancer by Semiglazov, V. V., Natopkin, A. A.

“…The article considers the aspects of selection of post-neoadjuvant therapy for patients with residual breast cancer depending on biological subtype and…”
Get full text

Intraoperative evaluation of the resection margin with the usage of digital two-point sectorography (Faxitron PathVision) by Bondarchuk, Ya. I., Zhiltsova, E. K., Krivorotko, P. V., Pesotskiy, R. S., Emelyanov, A. S., Tabagua, T. T., Gigolaeva, L. P., Yereshchenko, S. S., Komyakhov, A. V., Nikolaev, K. S., Zernov, K. Yu, Semiglazov, V. V., Paltuev, R. M., Mortada, V. V., Shaykhelislamova, L. F., Enaldieva, D. A., Amirov, N. S., Channov, V. S., Artemyeva, A. S., Chernaya, A. V., Ulyanova, R. Kh, Semiglazov, V. F.

“…Background . Surgery is fundamental in complex and combined approach in the treatment of the early breast cancer. It is a common fact, that absence of tumor…”
Get full text

Current approaches to the treatment of HER2‑positive breast cancer with brain metastases by Semiglazova, T.  Yu. , Sharashenidze, S.  M. , Kerimova, S.  N. , Klimenko, V.   V., Malygin, A. Yu. , Dashyan, G.  A. , Paltuev, R.   M., Semiglazov, V.  V. , Krivorotko, P.   V., Novikov, S.  N. , Semiglazov, V.   F.

“…The article discusses modern approaches in the treatment of HER2-positive breast cancer (BC) with brain metastases (BM).The patients are subject to…”
Get full text

Hereditary breast cancer and ovarian cancer: clinical course and treatment by Semiglazov, V. V., Protasova, A. Е., Kalikeev, G. K.

“…This article analyzes current problems associated with surgical and systemic treatment for hereditary breast and ovarian cancers (including those associated…”
Get full text

Use of a controlled negative pressure system for the treatment of periprosthetic breast complications by Chizh, I. A., Semiglazov, V. V., Kolarkova, V. V., Telishevskiy, A. V., Vinogradov, I. А., Gukova, V. V., Zakharenko, А. А., Kolarkov, А. V.

“…Background . One of the most common methods of breast reconstruction after mastectomy for malignant tumors is reconstruction using an endoprosthesis. However,…”
Get full text

Three-dimensional automated breast ultrasound – a supplemental screening tool by Busko, E. A., Semiglazov, V. V., Rozhkova, N. I., Dzhahilova, S. K., Akzyanova, E. R., Krivorotko, P. V., Ryazanov, V. V., Bagnenko, S. S.

“…Background. Three-dimensional automated breast ultrasound (ABUS) is an innovative technology that allows global visualization of the breast and eliminates the…”
Get full text

TIL’s in triple-positive breast cancer by Urezkova, M., Kudaybergenova, A., Semiglazova, T., Semiglazov, V., Tseluiko, A., Artemyeva, A.

Get full text

The role of tumor-infiltrating lymphocytes, prognostic and predictive signification in breast cancer by Tseluiko, A., Semiglazov, V., Kudaibergenova, A., Urezkova, M., Artemieva, A., Krivorotko, P.

Get full text

ADJUVANT HORMONE THERAPY ELIGIBILITY OF PREMENOPAUSAL WOMEN WITH ER+ BREAST CANCER by V. F. SEMIGLAZOV, V. V. SEMIGLAZOV, V. Y. LIFANOVA

“…Adjuvant endocrine therapy of premenopausal patients with ER+ breast cancer typically consists in administration of tamoxifen for 5 years. However, in cases of…”
Get full text

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial by Mackey, J.R., Pieńkowski, T., Crown, J., Sadeghi, S., Martin, M., Chan, A., Saleh, M., Sehdev, S., Provencher, L., Semiglazov, V., Press, M.F., Sauter, G., Lindsay, M., Houé, V., Buyse, M., Drevot, P., Hitier, S., Bensfia, S., Eiermann, W.

“…The optimal regimen for adjuvant breast cancer chemotherapy is undefined. We compared sequential to concurrent combination of doxorubicin and cyclophosphamide…”
Get full text